Share this video  

ASCO 2020 | Reduced postoperative therapy in patients with OPC: ECOG-ACRIN 3311

Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, USA, highlights data from the ECOG-ACRIN E3311 study (NCT01898494) which examined the use of reduced postoperative therapy in patients with intermediate risk p16+ oropharynx cancer (OPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).